studi cystic fibrosi use isoelectr focus iv distinct ciliari dyskinesia activ cystic fibrosi asthmat sera associ cystic fibrosi protein activ cystic fibrosi serum cystic fibrosi protein cfp ciliari dyskinesia activ cda sera cf homozygot heterozygot carrier individu bronchial asthma partial purifi concurr cda sera patient cystic fibrosi cf bronchial asthma shown differ substanc ion exchang gel permeat chromatograph procedur sephadex g200 chromatographi indic cfcda elut protein fraction molecular weight mw 68000150000 asthma cda found protein fraction mv greater 150000 two activ could also separ deaecellulos chromatographi prior acidif whole normal cf homozygot oblig heterozygot asthmat sera ph 37 use edta follow fraction sephadex g200 remov cda fraction highermolecular weight shift activ protein fraction mw 110013700 procedur afford 200fold purif cda sera patient asthma cf edta treatment howev also gener cda previous nonreact normal sera subsequ fraction variou activ g200 fraction biogel p10 allow separ three separ activ biogel fraction iiiv v fraction shown repres activ sera patient asthma determin c3a mw 9000 fraction also found normal cf carrier sera therefor specif cda fraction iiiv thought repres cfspecif cda mw 5000 sinc could demonstr either normal asthmat sera found sera oblig heterozygot fraction iiiiv also react antisera human c3a fraction v gener serum type upon acidif serum edta thought nonspecif cda biogel p10 filtrat sephadex g200 fraction provid 823fold 650 fold purif asthmat cf cda respect concurr analysi column fraction cda bioassay cfp electrofocus show cfp fraction contain cfcda combin analys employ acid disc gel electrophoresi isoelectr focus edta treatment activ cfimmunoglobulin ig g sephadex g200 column fraction follow biogel p10 chromatographi provid evid cfp associ cfcda unknown yet whether cfp respons cfcda activ